Han Cao - Bionano Genomics Founder, Chief Scientific Officer


USD 2.16  0.03  1.37%   

Dr. Han Cao is Founder and Chief Scientific Officer of the Company. From January 2000 to October 2003, Dr. Cao worked as a Research Fellow in the Nanostructure lab in the Department of Engineering at Princeton University. Dr. Cao was a postdoctoral fellow from October 2000 to December 2003 at the Institute for Human Gene Therapy, in the Department of Molecular and Cellular Biology at the University of Pennsylvania Medical Center
Age: 49  Founder Since 2011  Ph.D    
858 888 7600  https://www.bionanogenomics.com
Cao received his bachelor’s degree in molecular and cellular biology from the University of Science and Technology of China and his Ph.D. in molecular biology from the University of Delaware.

Bionano Genomics Management Efficiency

Bionano Genomics has return on total asset (ROA) of (16.09) % which means that it has lost $16.09 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (27.43) %, meaning that it created substantial loss on money invested by shareholders. Bionano Genomics management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 11.12 M in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Bionano Genomics has a current ratio of 12.73, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Bionano Genomics until it has trouble settling it off, either with new capital or with free cash flow. So, Bionano Genomics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Bionano Genomics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Bionano to invest in growth at high rates of return. When we think about Bionano Genomics' use of debt, we should always consider it together with cash and equity.
Bionano Genomics, Inc. provides genome analysis software solutions. The company was founded in 2003 and is headquartered in San Diego, California. Bionano Genomics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 299 people. Bionano Genomics (BNGO) is traded on NASDAQ Exchange in USA and employs 299 people.

Bionano Genomics Leadership Team

Elected by the shareholders, the Bionano Genomics' board of directors comprises two types of representatives: Bionano Genomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bionano. The board's role is to monitor Bionano Genomics' management team and ensure that shareholders' interests are well served. Bionano Genomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bionano Genomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Sean Paolino, Vice President - Finance
Han Cao, Founder, Chief Scientific Officer
Darren Cai, Independent Director
Warren Robinson, Chief Commercial Officer
Albert Luderer, Independent Director
Kristiina Vuori, Independent Director
Christopher Twomey, Independent Director
Mark Borodkin, COO
Quan Zhou, Independent Director
Junfeng Wang, Independent Director
Erik Holmlin, President CEO, Director
Mike Ward, Vice President - Corporate Development
R Holmlin, President CEO, Director
David Barker, Chairman of the Board

Bionano Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bionano Genomics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Bionano Genomics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Global Correlations Now


Global Correlations

Find global opportunities by holding instruments from different markets
All  Next Launch Module

Pair Trading with Bionano Genomics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bionano Genomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bionano Genomics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Bionano Genomics

+0.75AAgilent Technologies Fiscal Year End 28th of November 2022 PairCorr
+0.73JPMJP Morgan Chase Fiscal Year End 13th of January 2023 PairCorr

Moving against Bionano Genomics

-0.52JNJJohnson Johnson Earnings Call  Next WeekPairCorr
The ability to find closely correlated positions to Bionano Genomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bionano Genomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bionano Genomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bionano Genomics to buy it.
The correlation of Bionano Genomics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bionano Genomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bionano Genomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bionano Genomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Trending Equities. Note that the Bionano Genomics information on this page should be used as a complementary analysis to other Bionano Genomics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try CEO Directory module to screen CEOs from public companies around the world.

Complementary Tools for Bionano Stock analysis

When running Bionano Genomics price analysis, check to measure Bionano Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bionano Genomics is operating at the current time. Most of Bionano Genomics' value examination focuses on studying past and present price action to predict the probability of Bionano Genomics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bionano Genomics' price. Additionally, you may evaluate how the addition of Bionano Genomics to your portfolios can decrease your overall portfolio volatility.
Global Correlations
Find global opportunities by holding instruments from different markets
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
CEO Directory
Screen CEOs from public companies around the world
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Is Bionano Genomics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine Bionano Genomics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.